Connect with us

Spread & Containment

Aurora Announces Sponsorship of ALUS’ New Acre Project to Fund Community Environmental Initiatives

NASDAQ | TSX: ACB
Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced a New Acre Project sponsorship to support ALUS. The commitment is intended to fund environmental programs

Published

on



NASDAQ | TSX: ACB

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, today announced a New Acre Project sponsorship to support ALUS. The commitment is intended to fund environmental programs in the communities where Aurora facilities are located.

The sponsorship creates shared value for Aurora’s customers, consumers, and patients by taking action to address climate change, help communities solve local environmental challenges and protect biodiversity through the restoration of natural habitats.

“As a proudly Canadian company, and global leader, Aurora deeply values the communities where we work and live,” says Miguel Martin , CEO. “As corporate citizens, we have a responsibility to our environment beyond offsetting, whether that’s by improving processes within our business to be more environmentally-conscious or supporting our communities to thrive.”

With $50,000 support from Aurora, ALUS will steward 50 New Acre Project acres, helping to restore wetlands and grasslands, create pollinator and wildlife habitats, reforest, and establish other ecologically beneficial projects.

“Aurora’s New Acre Project sponsorship demonstrates leadership within the cannabis industry, taking a step forward to address climate change by helping communities solve local environmental challenges,” says Bryan Gilvesy , CEO of ALUS. “ALUS looks forward to working with Aurora to create a positive impact in the communities where they operate.”

To start, the sponsorship will focus on developing New Acres in Ontario and Alberta , where Aurora operates.

The Company has implemented several environmental initiatives internally, including investments in energy efficiency, water conservation and waste education; and is committed to continuous improvement.

About ALUS and New Acre TM Project :

ALUS (originally an acronym for Alternative Land Use Services) is a charitable organization that sustains agriculture and biodiversity for the benefit of communities and future generations. ALUS provides direct financial and technical support to a network of more than a thousand farmers and ranchers who deliver ecosystem services in more than 30 communities across Canada , such as cleaner air, cleaner water, carbon sequestration, erosion control, flood mitigation, pollinator support and wildlife habitat. ALUS’ New Acre Project helps corporations exceed sustainability objectives by supporting farmers and ranchers to build nature on their land. Learn more at newacre.org and ALUS.ca .

About Aurora:

Aurora is a global leader in the cannabis industry, serving both the medical and consumer markets. Headquartered in Edmonton, Alberta , Aurora is a pioneer in global cannabis dedicated to helping people improve their lives. The Company’s brand portfolio includes Aurora, Aurora Drift , San Rafael ’71 , Daily Special , MedReleaf, CanniMed, Whistler , Reliva and KG7 CBD . Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora’s brands continue to break through as industry leaders in the medical, performance, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on Twitter and LinkedIn .

Aurora’s common shares trade on the TSX and NASDAQ under the symbol “ACB” and is a constituent of the S&P/TSX Composite Index.

Forward-Looking Information

This news release includes statements containing certain “forward-looking information” within the meaning of applicable securities law (“forward-looking statements”). Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. Forward-looking statements made in this news release include statements regarding the implementation and expected outcomes of sponsored environmental programs, including value created for various stakeholders.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions managements considers to be reasonable.  Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer  sales channels, management’s estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management’s estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises, including the current outbreak of COVID-19, and other risks, uncertainties and factors set out under the heading “Risk Factors” in the Company’s annual information form dated September 27, 2021 (the “AIF”) and filed with Canadian securities regulators available on the Company’s issuer profile on SEDAR at www.sedar.com and filed with and available on the SEC’s website at www.sec.gov .  The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

SOURCE Aurora Cannabis Inc.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2021/12/c3971.html

News Provided by Canada Newswire via QuoteMedia

 

Cannabis Market Could Reach $5.5B By End Of Year

 
Experts Weigh In On Our Exclusive FREE Report. Can You Afford To Miss Out?
 

Read More

Continue Reading

Spread & Containment

When Will Royal Caribbean Bring Back an Adult Favorite Activity?

The cruise line has not brought back a popular very adult event, but there are signs that may change.

Published

on

The cruise line has not brought back a popular very adult event, but there are signs that may change.

Cruising has largely returned to what it was before the pandemic -- at least once you board the ship. Before you cruise, Royal Caribbean International (RCL) - Get Royal Caribbean Group Report, Carnival Cruise Lines (CCL) - Get Carnival Corporation Report, Norwegian Cruise Line (NCLH) - Get Norwegian Cruise Line Holdings Ltd. Report, and the other lines sailing from U.S. ports still require would-be passengers to check some boxes.

First, all passengers 12 and over must be fully vaccinated at least two weeks before the ship sails. Boosters are not required, but passengers do have to show their original vaccine cards. In addition, anyone sailing must show a negative covid test taken no more than two days before their sailing.

Proving you have met those requirements makes boarding a bit more of a chore, especially because some passengers do not have their documents in order. After you pass the boarding hurdles, however, being on a cruise feels almost entirely like what it did before the pandemic.

Masks are optional for passengers and capacities have inched back toward normal. Crew members remain masked and social-distancing signs are still up, but nobody is social distancing anymore. 

And nearly all activities have returned -- but a few guest favorites have not.

Dukas/Universal Images Group via Getty Images

What Is Royal Caribbean's 'The Quest?'

Before the pandemic, Royal Caribbean offered an adults-only game show called "The Quest." It's a well-loved risque event that's sort of shrouded in secrecy. You're not supposed to take pictures or video, but lots of videos are on the internet.

A number of members of the message-boards section of the Royal Caribbean Blog attempted to explain the event:

"It's basically this giant scavenger hunt within your team. On Oasis it was in Studio B. There are 6ish couples who are team leads, and the cruise director shouts out tasks --things to find in the audience, or things to accomplish. For example, 6 ladies bras, or 3 shoelaces tied together. The team leads have a card with their number on it, and as soon as the task is done/found, they run up to the cruise director with the object and the card, wave it in his face. The fastest teams get more points," wrote hmills96.

It can get a bit raunchy, according to Jerel.

"It's a adult oriented game show where people willingly makes fools of themselves," he wrote. "...It doesn't take long before they are asking for girls who are wearing red thongs and to prove it on stage, or even ask a captain to produce 4 bras, many women will quickly rip them off btw. Also it's pretty much guaranteed to see men dirty dancing with each other and/or hairy men dressed up in women's clothing."

The post also noted that some people may have regrets the next day.

"It tends to be on the last night, I assume because you may not want to be seen in public the next day," he added.

Will Royal Caribbean Bring 'The Quest' Back?

"The Quest" involves a lot of people in a fairly small space, with touching a body a key part of the game. That's not a great look for the cruise line, even if social distancing has largely gone away on cruise ships.

Cruise-line personnel have told passengers that "The Quest" would return, but no timetable has been given. 

Multiple crew members noted that Studio B, where "The Quest" takes place on most ships, has been used for show rehearsals. Various productions have struggled to get to their full complement of cast or have had to integrate understudies due to positive covid tests.

The company has not made any official statement on "The Quest," but numerous crew members/activity personnel have said that it would come back.

For now, "The Quest," and balloon drops on the Royal Promenade along with certain parties in that same central corridor remain casualties of the pandemic. 

Balloon drops have been tested on some ships but have not formally returned while "The Quest" remains in the cruise line's plans, but it does not yet have a return date.

Read More

Continue Reading

Spread & Containment

Monkeypox may not mutate as fast as coronaviruses, but that doesn’t mean it can’t adapt to its new hosts

Monkeypox may not churn out variants at the rate of SARS-CoV-2, but that doesn’t mean we can rest easy.

Published

on

The recent outbreak of monkeypox virus has called into question the capabilities of these kinds large DNA viruses to evolve, adapt and change their biology.

Compared with small RNA viruses such as coronavirus, monkeypox virus and other large DNA viruses are thought to evolve slowly. Yet there’s clear evidence that this really isn’t a hindrance to these viruses. In fact, they can adapt to new environments like us.

Although most infections remain mild, monkeypox can be a serious life-threatening disease, resulting in sepsis, encephalitis (brain inflammation) and blindness. The most common symptoms are rash and skin lesions, alongside flu-like symptoms and swollen lymph nodes.

Cumulative monkeypox cases in current outbreak

Our World in Data, CC BY

Monkeypox virus naturally infects wild rodents, such as squirrels and rats, in west and central Africa – but it can jump species into humans and other animals. However, once it has jumped to humans, it cannot keep transmission going and eventually outbreaks die out. This is probably because monkeypox has not adapted itself to its new environment of humans, as spillback into wild rodents from infected humans is unlikely.

Monkeypox is closely related to the viruses that caused smallpox (variola viruses) and the virus that we use to vaccinate and eradicate smallpox (vaccinia virus). This group of viruses, referred to as poxviruses, are a kind of large DNA virus, meaning that their genome is composed of a chemical known as DNA, like our genome. (Coronavirus and related viruses use a cousin molecule called RNA.)

Other DNA viruses are the large DNA viruses adenoviruses and herpesviruses, but also small ones like papillomaviruses and parvoviruses. The viral genomes composed of either DNA or RNA essentially are the instructions to make new viruses, infect us and cause disease. Changes to the instructions can change virus biology.

As we have seen with SARS-CoV-2 and its variants, viruses can change how they behave with regards to spreading, disease severity and vaccine sensitivity. This is because of changes accumulating in the virus genome. Virus replication generates diversity in its genome, which can be acted on by evolutionary forces such as natural selection, to increase in frequency and maybe even out-compete older versions.

Evolutionary changes can occur when the virus encounters a new environment that it is not fully adapted to. Although all viruses can evolve rapidly due to their vast population sizes and rapid generation times, RNA viruses are thought to be masters of evolution because they have high mutation rates due to their small size, and many often lack error-correcting ability meaning more mutations occur every time they replicate.

Poxviruses have some characteristics that make them more generalist, including stable infectious particles, giving them more chances to infect. They use very common molecules on your cells to gain entry and infect, unlike SARS-CoV-2 which needs the specific ACE2 protein to gain entry to our cells.

Large DNA viruses such as monkeypox also contain lots of genes that target and manipulate different parts of the immune system.

Room for improvement

However, there’s clear evidence that improvements can be made, because, in humans, monkeypox transmission is relatively inefficient, with long incubation periods.

In general, large DNA viruses such as monkeypox are no different from other viruses, and their mutability is the basis for our ability to track and trace monkeypox outbreaks. They make mistakes and errors accumulate, which can be used as fuel for evolution and biological changes. There’s even evidence from the recent monkeypox outbreak that the host cell is directly mutating the virus genome.

Studies focusing on related poxviruses like the vaccinia virus have even uncovered new tricks they can use, which include rapidly amplifying the number of genes they use to attack our immune system. They could even borrow some of our own genes to help them infect us.

We can’t predict the trajectory that monkeypox evolution will take, so we must take the threat of this virus adapting to its new hosts (humans) seriously. And we need to use all the public health tools at our disposal to halt the current outbreak in all countries – including those where it is endemic.

Connor Bamford receives funding from UKRI, Wellcome Trust, British Medical Association Foundation, SFI.

Read More

Continue Reading

Spread & Containment

Analysis: The next COVID booster shots will likely be updated for Omicron

COVID-19 vaccines this fall are likely to be based on the Omicron variant of the coronavirus rather than the original strain, although some experts suggest…

Published

on

Analysis: The next COVID booster shots will likely be updated for Omicron

By Michael Erman

NEW YORK, June 24 (Reuters) – COVID-19 vaccines this fall are likely to be based on the Omicron variant of the coronavirus rather than the original strain, although some experts suggest they may only offer significant benefits for older and immunocompromised people.

Moderna (MRNA.O), Pfizer (PFE.N) and Novavax (NVAX.O) have been testing vaccines based on the first BA.1 Omicron variant that became dominant last winter, driving a massive surge in infections.

On Wednesday, Moderna said its updated vaccine worked well against more recent Omicron subvariants, and that it was moving forward with plans to ask regulators for approval. read more

Test tubes are seen in front of displayed Pfizer and Biontech logos in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo

Vaccines that can bridge the gap between the original version of coronavirus and the Omicron variant would likely be “far, far better” for the fall, according to Trevor Bedford, a biologist at the University of Washington who has closely tracked mutations of the SARS-coV-2 virus.

Bedford said it would take too long to meet regulatory requirements for a switch to tailor the next vaccine to versions of Omicron spreading quickly now.

“Catching up to any of the Omicrons is really important,” he said, noting the enormous jump in the number of mutations from the original strain that emerged in China to Omicron on the spike protein part of the virus the vaccines target.

The World Health Organization (WHO) plans to assess the effectiveness of vaccines built for Omicron, as do national health regulators like the U.S. Food and Drug Administration.

A group of WHO advisers said last week an Omicron-based vaccine may broaden immunity after the Omicron variant evaded much of the protection against infection generated by the vaccines designed for the original virus, a view other experts share. FDA scientific advisers will meet on June 28 to make a recommendation on the issue.

Important questions remain, including whether vaccines designed for variants circulating last winter will work well against significantly different subvariants that may emerge. Experts also want to know if the new shots will increase protection against severe disease and death for younger, healthier people or merely offer a few months additional safeguard against mild infection.

Scientists who have questioned the value of booster shots for young and healthy people say a broad campaign is not needed with an updated shot either.

BILLIONS OF DOLLARS AT STAKE

Unlike annual adjustments for influenza vaccines that manufacturers are allowed to try to align with circulating strains, regulators have asked companies to run clinical trials to prove their new COVID vaccines work better.

But nearly three years into the pandemic, vaccine makers are pushing for a flu-like model that would allow them to nimbly retool their shots to combat new variants.

At stake are billions of dollars in contracts with countries around the world. Moderna is already manufacturing the shots, with deals signed in some countries.

Moderna is asking regulators to greenlight a version of their COVID-19 shot targeting both the BA.1 Omicron variant and the original version of the virus, armed with fresh evidence it may be effective against more recently circulating subvariants.

“The challenge we have is the virus continues to evolve really quickly,” Moderna President Stephen Hoge said in an interview, noting that millions of doses of the updated vaccine could be ready in August.

If the drugmaker needs to tweak the vaccine further and restart manufacturing, new shots may not be available until the middle of the fourth quarter, he said.

Pfizer and partner BioNTech (22UAy.DE) are testing variant-adapted COVID-19 vaccines but have yet to release any data. Novavax, whose vaccine is not yet authorized for U.S. use, launched a trial of its own Omicron-based vaccines in late May.

Dr. Jesse Goodman, a professor at Georgetown School of Medicine and a former top FDA scientist, said unlike for flu, regulators do not have enough experience with COVID vaccines to match them to circulating strains without clinical trials.

Dr. Luciana Borio, former acting chief scientist of the FDA, said the science generally supports the idea that it would be better to have vaccines that more closely match the currently circulating virus.

“We see that with people that have hybrid immunity from vaccination plus infection,” Borio said. “The immune response that is generated is very rich.”

Still, Borio and others are not convinced everyone should be vaccinated again.

“There’s no evidence that a healthy 27-year-old person needs to be revaccinated,” Borio said.

Reporting by Michael Erman Editing by Caroline Humer and Bill Berkrot

Our Standards: The Thomson Reuters Trust Principles.

Read More

Continue Reading

Trending